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STATEMENT OF CLINICAL RELEVANCE 
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Anthracyclines are a widely used chemotherapeutic class, but can cause life threatening 
congestive heart failure (CHF). The risk of serious cardiac damage has spurred the 
implementation of competing non-anthracycline regimens; although many patients still benefit 
from anthracyclines based on risk or underlying biology of the tumor. Germline genetic 
biomarkers for CHF have been studied, but their ability to reliably predict risk remains unclear as 
populations studied have been underpowered and heterogeneous, with inconsistent results to 
date. We have identified a SNP, rs28714259 that is associated with CHF risk. This SNP was 
identified through a GWAS from the randomized phase III adjuvant breast cancer trial E5103, 
and was subsequently validated in two independent phase III adjuvant breast cancer trials; 
E1199, and BEATRICE. rs28714259 is associated with increased risk of anthracycline induced 
CHF and might be useful to guide appropriate usage of anthracyclines for patients with breast 
cancer in the curative setting.  
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ABSTRACT 
 
Purpose: Anthracycline-induced congestive heart failure (CHF) is a rare but serious toxicity 
associated with this commonly employed anti-cancer therapy. The ability to predict which 
patients might be at increased risk prior to exposure would be valuable to optimally counsel risk 
to benefit ratio for each patient. Herein we present a genome wide approach for biomarker 
discovery with two validation cohorts to predict CHF from adult patients planning to receive an 
anthracycline.  
 
Experimental Design: We performed a genome wide association study (GWAS) in 
3431patients from the randomized phase III adjuvant breast cancer trial E5103 to identify SNP 
genotypes associated with an increased risk of anthracycline-induced CHF. We further attempted 
candidate validation in two independent phase III adjuvant trials, E1199 and BEATRICE.  
 
Results: When evaluating for cardiologist adjudicated CHF, 11 SNPs had a p-value <10-5 of 
which nine independent chromosomal regions were associated with increased risk. Validation of 
the 2 top SNPs in E1199 revealed one SNP, rs28714259 that demonstrated a borderline 
increased CHF risk (p=0.04, OR=1.9).  rs28714259 was subsequently tested in BEATRICE  and 
was significantly associated with a decreased left ventricular ejection fraction (p=0.018, 
OR=4.2).  
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Conclusion: rs28714259 represents a validated SNP that is associated with anthracycline-
induced CHF in three independent, phase III adjuvant breast cancer clinical trials. 
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INTRODUCTION 
Anthracyclines are a widely used chemotherapeutic class. Despite substantial anti-tumor activity, 
anthracyclines are not without toxicity. Cardiotoxicity, including congestive heart failure (CHF), 
is a dose-limiting side effect (1). Patients that received an anthracycline were five-times more 
likely to develop cardiac symptoms (2). The overall incidence of CHF in patients receiving a 
cumulative dose of 240-360mg/m2 of doxorubicin is 1.7-2.1% (3). The optimal definition of 
cardiac dysfunction is debatable but the most common mode of evaluation includes assessment 
of left ventricular ejection fraction (LVEF). Unfortunately, even with expert interpretation, there 
is variability in its estimation (4).   
 
Anthracycline-induced cardiotoxicity can occur in two distinct forms: acute toxicity that 
develops early and presents as arrhythmias or depressed LVEF, or chronic toxicity, that occurs 
years later. The mechanism of cardiotoxicity is likely related to oxidative stress although not 
completely elucidated (5). Known risk factors for developing clinical cardiomyopathy include 
cumulative dose, age, history of cardiac conditions, hypertension, liver disease, and mediastinal 
radiotherapy (5, 6). Risk of a cardiac event is further increased when anthracyclines are 
combined with other therapies, including trastuzamab (7) and bevacizumab (8, 9).  
 
The risk of serious, irreversible cardiac damage has spurred the implementation of competing 
non-anthracycline regimens to obviate this concern (10) , although many patients still benefit 
from anthracyclines based on risk or biology. The severity of the side-effect necessitates a means 
to identify high risk patients. Germline genetic biomarkers for CHF have been studied, but their 
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ability to reliably predict risk remains unclear as populations studied have been heterogeneous 
and results inconsistent(11-22).  
 
We report a comprehensive evaluation of a large phase III, adjuvant breast cancer trial, 
E5103(9), to identify common single nucleotide polymorphisms (SNPs) that are associated with 
the risk of anthracycline-induced CHF.  We performed a genome-wide association study 
(GWAS), which assessed SNPs throughout the genome. Furthermore, we tested our most 
promising SNPs in two independent, randomized phase III trials, E1199 (23) and BEATRICE (8) 
, which used a similar anthracycline backbone.  
 
MATERIAL and METHODS 
Genome wide association study to identify common variants in ECOG-5103 
E5103 Overview 
E5103(9) was a phase III adjuvant breast cancer trial that randomized 4994 patients to 
doxorubicin (60 mg/m2)  and cyclophosphamide (AC) for four cycles, followed by 12 weeks of 
weekly paclitaxel (Arm A) or to the same chemotherapy with either concurrent bevacizumab 
(Arm B) or concurrent plus sequential bevacizumab (Arm C). Patients were allowed to receive 
AC every two or three weeks at the discretion of the treating physician and patients from all arms 
were scheduled to receive the same cumulative dose of doxorubicin Table 1. Analyses were 
performed across all arms to identify SNPs associated with CHF. This correlative study was 
approved by the Indiana University IRB.  
 
E5103 genotyping and imputation 
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Due to the availability of germline DNA, genotyping was performed at two independent time 
points in non-overlapping study subsets (Figure 1). DNA from an initial 2209 and an additional 
1222 patients was genotyped by Illumina Genotyping Services using the HumanOmni1-Quad 
(>1 million SNPs) and the HumanOmniExpress (730,525 SNPs) array, respectively. Both sample 
sets used the Illumina BeadChip microarray platform for genotyping and the Illumina 
GenomeStudio software for initial genotyping calls. Of note, SNPs on the HumanOmniExpress 
were a subset of those on the HumanOmni1-Quad. Those SNPs not on the HumanOmniExpress 
were imputed in the second sample subset (Supplemental data).  
 
E5103 case and control definitions for CHF 
To be selected for inclusion in E5103, patients must have not had a history of clinically 
significant cardiovascular disease. Cardiovascular health was monitored at the start and during 
the trial by MUGA or echocardiograms. Additionally, a cardiac symptoms assessment was 
performed two years post-registration. Cardiac events including: CHF, decrease in LVEF, acute 
coronary syndrome, supraventricular tachycardia and myocardial dysfunction, were diagnosed 
by a cardiologist. Cases to be considered for this correlative study included individuals that had 
centrally reviewed, cardiologist-adjudicated CHF. Controls were strictly defined and included 
patients who did not experience CHF or other reported events of cardiotoxicity including: LVEF 
<50% or drop in LVEF ≥20% from baseline. All controls received the full intended dose of AC 
with no modification.  
 
Statistical analysis 
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A case-control GWAS was performed in the genetically defined European American (EA) 
subsamples (Supplement Material) to identify SNPs associated with the presence or absence of 
CHF. Age, menopausal status, experimental arm, tumor grade, body surface area (BSA), 
hypertension during therapy and use of anti-hypertension medications at baseline or anti-
hypertensive therapy added during treatment, were considered as covariates in analyses. The p-
value threshold was < 0.05 for inclusion of covariates in the regression model. SNPs available on 
the HumanOmni1-Quad array were used as the common basis for all statistical analysis. An 
additive model of SNP effect was used when testing all hypotheses. The case-control analysis 
was conducted using SNPTEST v2.4 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). SNP and sample quality 
control (QC) were performed as previously (24) and outlined in Supplemental Material.  
 
Validation in E1199  
Overview of E1199  
E1199(23) was a phase III adjuvant breast cancer trial that randomized 5052 patients with node-
positive or high-risk, node-negative breast cancer to one of four treatment arms. First, all patients 
received doxorubicin (60 mg/m2) and cyclophosphamide (AC) for four cycles followed by 
paclitaxel every three weeks for four cycles, or paclitaxel weekly for 12 cycles, docetaxel every 
three weeks for four cycles, or docetaxel at weekly for 12 cycles. Tumor derived DNA (formalin 
fixed paraffin embedded) was available from 2906 patients; Figure 1 
 
Candidate validation of top SNPS in E1199  
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All association results were reviewed and priority were given to two SNPs with further evidence 
of association from other top SNPs (p-value <10-5) in linkage disequilibrium (LD) to reduce the 
risk of false positive signals from technical genotyping errors; Figure 2. These two SNPs were 
genotyped using the QuantStudio™ 12K Flex OpenArray® AccuFill™ System (Thermo Fisher 
Scientific) platform.   
 
E1199 case and control definitions for CHF  
To be included in E1199, patients must have not had a history of myocardial infarction, CHF or 
significant ischemic or valvular heart disease. Cases included patients with reported CHF as 
defined by the Common Toxicity Criteria version 2.0. Raw LVEF data points were not available. 
Patients were considered controls if they had no reported cardiac events and received the full 
dose of intended AC with no dose modification.  
 
Statistical analysis 
Comparing cases and controls in the EA subpopulation, logistic regression analysis was 
performed to identify SNPs associated with CHF. Age, BSA and treatment arm were considered 
as covariates. The p-value threshold for significance was set at 0.025 after Bonferroni correction 
was made.   
 
Validation in BEATRICE  
Overview of BEATRICE  
BEATRICE(8) was a phase III adjuvant breast cancer trial that randomized 2591 patients to a 
minimum of four cycles of standard adjuvant chemotherapy (including an anthracycline, taxane 
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or both) at the investigator’s discretion with or without bevacizumab for one year. Germline 
DNA was available from 828 patients; Figure 1.     
 
Candidate SNP validation in BEATRICE  
The SNP with borderline association with CHF in the E1199 was further tested for association 
with decreased LVEF in BEATRICE; Figure 2. The SNP was genotyped using a TaqMan SNP 
assay. 
 
BEATRICE case and control definitions for CHF  
To be included in BEATRICE, patients had a baseline LVEF >55%. In the parent trial, CHF was 
defined as New York Heart Association (NYHA) class III or IV CHF accompanied by a drop in 
LVEF> 10% to below 50. There were only 16 cases of NYHA CHF or cardiac death across the 
parent trial and therefore insufficient cases in the cohort of genotyped patients. Thus we enriched 
statistical power by including cases based on low LVEF. Prior to genetic analysis, we selected 
LVEF <45% to be considered an event. Because of inconsistency and inaccuracy of LVEF 
measurement, we did not select <50%, a commonly used criterion for mild dysfunction, to 
minimize false positive events. We also chose 45% based on prior data suggesting that LVEF 
<45% was a strong contributor to future cardiovascular risk (25). Patients were considered 
controls if they had no reported cardiac events, had no hypertension and received the full dose of 
intended anthracycline without dose modification.  
 
Statistical analysis 
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Comparing cases and controls in the EA subpopulation, logistic regression analysis was 
performed to identify SNPs associated with decreased LVEF. Age, BSA and treatment arm were 
considered as covariates. Since only one statistical comparison was performed, statistical 
significance was set at a p-value <0.05.  
 
RESULTS 
 
Phenotypes: rate of CHF and clinical predictors 
E5103: Of 4033 patients who had available DNA (Figure 1), phenotype data were available only 
from 3394 genotyped patients. In this subgroup, 2% experienced cardiologist-adjudicated CHF 
(Table 1). This included 68 cases; 51 EA, 13 African Americans (AA) and 4 of other race. There 
was no increased risk across the genetically determined racial groups (EA vs. AA vs. other; p-
value=0.50). Due to the insufficient number of non-EA cases, genetic association analysis was 
limited to the EA subgroup. Non-genetic demographic predictors were compared for the entire 
group as well as for EAs and AAs separately (Table 2). Older age was a significant risk factor, 
with a 43% relative increased risk with each decade of life (p=0.009). There was an increased 
risk in arm C (p=0.04) but not in arm B (p=0.87) when compared with arm A. There was an 
increased risk for patients who were on anti-hypertensives at baseline (p=7.2×10-4) but not for 
those patients who experienced therapy-induced hypertension. BSA was not associated with an 
increased risk in the entire cohort (p=0.10) or in EA patients (p=0.79) but was associated with 
increased risk in AA patients (p=0.01).  
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E1199: Phenotypic data were available from a majority of patients in the parent trial (n=4735) as 
well as the entire genotyped group (n=2906); Figure 1. The risk of CHF was 1.5% in the parent 
trial and 1.6% in the genotyped group (Table 1). In the genotyped group, there were 47 cases of 
CHF; 38 among self-defined EA and 7 cases in AA and 2 cases among other races. There was no 
significant increase in risk based on race (EA vs. AA vs. other; p-value=0.09). Again, genetic 
association analyses were limited to the EA subgroup due to an insufficient number of non-EA 
cases. Non-genetic demographic predictors were compared for the entire group as well as for 
EAs and AAs separately (Table 2). Older age demonstrated a 39% relative increased risk with 
each decade of life in the parent population (p=0.005). BSA was not associated with risk in the 
EA population (p=0.61) but a trend for increased risk in the AA population (p=0.07). Neither 
hypertension nor use of anti-hypertensive data was available in this trial.  
 
BEATRICE: Phenotypic data were available only from the 828 genotyped patients (Figure 1).  In 
this subgroup of patients, 2.9% experienced a decline in LVEF <45%. This value is higher than 
the 1.6% of population reported to experience NYHA class III or IV CHF in the parent trial (8) 
(Table 1). The subgroup included a total of 24 cases; 21 among self-defined EA and the 
remaining 3 were of other race. There was no increased risk of CHF across the self-defined racial 
groups (EA vs. other; p-value=0.45). Because of insufficient numbers of cases, the genetic 
association analyses were limited to the EA subgroup. Non-genetic demographic predictors were 
compared for the entire group as well as for EAs and AAs separately (Table 2). Older age 
(p=0.77) and increased BSA (p=0.91) were not associated with increased likelihood of decreased 
LVEF. There was also no increased risk for those who experienced significant therapy-induced 
hypertension (p=0.98).   
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GWAS results for CHF in E5103 
After genotyping and quality control (QC), 810,907 SNPs were used for the GWAS in E5103.  
The strength of association between genotype and CHF (Figure 3) are demonstrated in Table 2. 
112 SNPs had a p-value <1×10-4 of which 99 were associated with increased risk of CHF 
(OR=1.4-3.7) (Supplemental table 1). Nine independent chromosomal regions represented by 
eleven top SNPs were associated with the risk of CHF (p-value <10-5) and in two of the nine 
regions, there are multiple SNPs that are in LD with top SNPs and also provide evidence of 
association; therefore, the likelihood of a false positive association is substantially reduced. One 
SNP from each of these two regions was selected for validation in independent data sets; Figure 
2. SNPs previously reported to be associated with anthracycline-induced CHF did not provide 
evidence of association in this study; Table 3.  
 
Evaluation of candidate SNPs in E1199 and BEATRICE 
One of the two SNPs genotyped in the E1199, rs28714259, provided evidence of borderline 
association with CHF (p = 0.041, OR = 1.9), whereas the other, rs6883259, was not (p=0.50). 
rs28714259 was subsequently genotyped in BEATRICE and was significantly associated with 
decreased LVEF <45% (p=0.018, OR=4.2) (Figure 2).  
 
DICUSSION 
In the present study, we aimed to identify a population at risk for developing CHF from 
anthracyclines using the dose and schedule commonly employed for adult solid tumors. We 
performed a GWAS in a large randomized phase III adjuvant trial. As a follow-up, we performed 
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limited genotyping in two large independent phase III adjuvant trials. In total, the three large 
trials enrolled over 12,500 breast cancer patients. All patients in E5103 and E1199 received a 
uniformed dose of doxorubicin (60 mg/m2) and over 95% patients in BEATRICE received an 
anthyracycline. We provide evidence that the SNP, rs28714259, is associated with cardiac 
dysfunction across trials using slightly different phenotype definitions. This SNP was among the 
top SNPs associated with increased risk of CHF (OR>1) and also had LD support from another 
top SNP in our discovery sample set of E5103 trial. In all three trials, the A allele was associated 
with an increased risk of cardiac damage: E5103 (OR=2.1; p=9.25×10-6), E1199 (OR=1.9; 
p=0.04) and BEATRICE (OR=4.2; p=0.02).  
 
Age was the most consistent demographic predictor for increased risk as it was associated in two 
of the three trials evaluated here. There was also a correlation between use of anti-hypertensive 
agents at baseline in E5103 but an increased risk was not seen for those who only had treatment 
induced hypertension. This would support the notion that underlying and potentially long term, 
cardiovascular disease increased the risk of this toxicity. Unfortunately details of comorbidities 
were not available for further evaluation. There was also a signal that BSA may be an important 
contributor but was only detected in the AA patients.  
   
Previous studies have evaluated germline predictors. This included evaluation of candidate SNPs 
or gene panels in the metabolism and transport pathway or in the proposed mechanistic pathways 
of anthracycline-induced cardiomyopathy (12-21, 26). Several of these studies have 
demonstrated associations, but none of these candidates were identified in the recent GWAS by 
Aminkeng et al.(11) or in our study (Table 3). Aminkeng et al. focused on a pediatric population 
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of EAs with 34 cases of decreased LVEF and 248 controls (11). The study identified a SNP in 
RARG (OR=4.7) that was confirmed in two other independent cohorts. Our current study found 
the opposite effect (decreased rather than increased risk) for the RARG SNP (p=4.1×10-6; 
OR=0.11). There are multiple explanations for the incongruence of findings across studies. One 
likely reason is due to the general heterogeneity in studies, including: drug type, drug exposure, 
phenotype definition and population. With regard to the latter, many of the prior studies to date 
have focused on the pediatric patient population.  
 
This study adheres to stringent criteria for biomarker discovery and the correlative study has 
several strengths as outlined (27).  First, the discovery cohort was conducted in the context of a 
randomized, phase III adjuvant trial, using a standard number of doses and cycles of 
doxorubicin. The phenotype collection mandated close follow-up of cardiac function with serial 
echocardiography and events defined by cardiologist adjudication based on both imaging and 
clinical picture. The genomic evaluation implemented a comprehensive genome wide approach, 
which allowed for unbiased discovery. The top finding was further supported in two independent 
trials that had the same (E1199) and similar (BEATRICE) doses and schedules of anthracycline.  
 
There were also several weaknesses. First, two of the three trials included an experimental arm 
that delivered bevacizumab. Thus, an association with cardiac toxicity due to the combination of 
an anthracycline plus bevacizumab cannot be excluded. This concern is substantially minimized 
as we adjusted for arm of study for both bevacizumab-containing trials, E5103 and BEATRICE,  
and the third trial, E1199, only included anthracycline; with the SNP being associated with an 
increased risk and similar effect size across all three trials. Second, the DNA from E1199 was 
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derived from tumor DNA and thus point mutations at the SNP site of interest and loss of 
heterozygosity cannot be excluded. This limitation was minimized by assuring meticulous QC of 
genotyping and that all analyzed SNPs did not violate HWE. Finally, we used slightly different 
definitions of cardiac dysfunction across the three trials. E5103 utilized a clinically useful 
definition of CHF as defined by a centrally reviewed, cardiologist adjudication and considered a 
composite of both symptoms and depressed LVEF. E1199 utilized the CTC criteria for CHF and 
BEATRICE employed the NYHA criteria to define cardiac damage. BEATRICE also collected 
raw LVEF values to further refine cases and controls; whereas E1199 did not. Despite the 
heterogeneity of phenotype, the similar results across the three trials strengthen the clinical 
generalizability of this genetic predictor.  
 
Our top SNP, rs28714259, lies in an intergenic region in chromosome 15 and had LD support 
from nearby SNPs (Figure 3B). There is increasing evidence that intergenic regions play an 
important role in gene expression and regulation through long-range interactions (28). Chromatin 
immunoprecipitation data from the ENCODE project revealed that rs28714259 is within the 
binding site for glucocorticoid receptor (GR) protein (29). Recent studies have demonstrated 
glucocorticoid signaling plays important roles in the structural and functional maturation of the 
fetal heart and in the maintenance of proper cardiac function in various animal models (30).  
 
Future confirmatory studies might focus on even less severe phenotypes of cardiac damage, as 
prior data demonstrates that asymptomatic CHF has marked increase 10-year mortality (31). 
Rare toxicities, however, might be best explained by rare variants with large effect size and these 
are not evaluated on current GWAS platforms. Thus additional work evaluating the role of rare 
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variants and mechanistic work is warranted and ongoing. The ability to better understand which 
patients might be at higher risk for this serious toxicity is an important step toward personalizing 
therapy and providing better care for our patients. 
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Table 1. Summary of CHF definitions and events across the clinical trials   
 
LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; GWAS=genome 
wide association study 
 
 
 
  
Trial Definition of CHF 
Cumulative 
dose of 
anthracycline 
Frequency  
of events 
 
Bevacizumab 
administered 
E5103 
Centrally reviewed, 
cardiologist –
adjudicated 
(Composite of 
symptoms and lowered 
LVEF) 
All patients 
received 240 
mg/m2 of 
doxorubicin 
  
2.0% 
Two of the three 
study arms  
     
 
E1199 
 
Common toxicity  
criteria v. 2.0 
All patients 
received 240 
mg/m2 of 
doxorubicin 
 
 
Parent trial: 1.5% 
No GWAS subgroup: 1.6% 
 
     
 
 
 
BEATRI
CE 
Parent trial:  
NYHA class 3/4 CHF 
 
94.8% of 
patients 
received an 
anthracycline 
at various 
doses per 
physician`s 
choice 
Parent trial: 1.6% 
One of the two 
study arms  
 Current GWAS:  
LVEF <45% 
GWAS subgroup: 2.9% 
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Table 2. Comprehensive comparisons of non-genetic demographic predictors of CHF 
 
 
*Clinical data was only available for those patients who had companion DNA samples 
AA=African American; EA=European American; BSA=Body Surface Area 
 
 
Clinical Trial 
 Samples with clinical data available 
 All  AA  EA 
 Age BSA  Age BSA  Age BSA 
E5103* 
(genotyped) 
N=3394 (68 cases) 
AA=386 (13 cases) 
EA=2525 (51 cases) 
Others=484 (4 cases) 
 
0.009 0.10 
 
0.76 0.01 
 
0.002 0.79 
E1199 
(Parent trial) 
N=4735 (71 cases) 
 AA=401 (11 cases) 
EA=4042 (58 cases) 
Others=292 (2 cases) 
 
0.005 0.04 
 
0.62 0.10 
 
0.005 0.48 
E1199 
(genotyped) 
N=2906 (47 cases) 
AA=267(38 cases) 
 EA=2616 (7 cases) 
Others=23 (2 cases) 
 
0.044 0.07 
 
0.50 0.07 
 
0.08 0.61 
BEATRICE* 
(genotyped) 
N=828 (24 cases) 
AA=31 (1 case) 
EA=705 (21 cases) 
Others=92 (2 cases) 
 
0.774 0.91 
 
0.99 0.99 
 
0.87 0.72 
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Table 3. Selected SNPs previously reported to be associated with congestive heart failure  
Study 
Number of 
Patients 
(sample 
size) 
Study Set  
Dose and 
Schedule of 
Anthracyclines 
Phenotype Genotype 
Genes of top 
association 
Validation 
with number 
of 
independent 
cohort  
Wojnows
ki et al.1 
450 DSHNHL-B1/B2 Doxorubicin/  
uniform dose & 
schedule 
WHO grade 3 
and 4 
cardiotoxicity 
Candidate SNPs in 
82 genes in 
anthracycline 
pharmacodynamics 
NADPH, BCC1, 
ABCC2 
No 
Blanco et 
al.2 
145 Retrospective 
pediatric cohort  
Any anthracycline/ 
Variable dose & 
schedule  
Self-reported 
symptoms  
Candidate genes 
NQO1, CBR3  
CBR3  No 
Rajić V 
et al.3 
76 Retrospective 
pediatric cohort  
Any anthracycline/ 
variable dose & 
schedule  
Cardiologist 
defined cardiac 
damage  
Candidate SNPs in 
SOD2, CAT, 
GSTT1, GSTM1 
CAT No 
Blanco et 
al.4 
487 COG-
ALTE03N1 
Any anthracycline/ 
variable dose & 
schedule  
AHA guidelines Candidate SNPs in 
CBR3 and CBR1 
CBR3 No 
Semsei et 
al.5 
235 Retrospective 
pediatric cohort  
Doxorubicin & 
Daunorubicin / 
uniform dose & 
schedule 
Cardiac function 
measured by 
LVFS 
Candidate SNPs in 
ABCC1  
ABCC1 No 
Visscher 
et al.6 
156 Retrospective 
pediatric cohort  
Doxorubicin & 
Daunorubicin/   
Variable dose & 
schedule 
CTCAE v3 Candidate SNPs in 
220 genes in 
anthracycline 
pharmacodynamics 
CBR3, CB4, 
HMNT,ABCC1, 
LC28A3 
Yes-Two 
cohorts 
Volkan-
Salanci et 
al.7 
70 Prospective adult 
cohort  
Doxorubicin / 
Variable dose & 
schedule 
Various 
measures of 
cardiac function  
Candidate SNPs in 
CBR3 and GSTP1 
CBR3, STP1 Yes  
 
Armenia 
et al.8 
255 Retrospective 
adult cohort  
Any anthracycline/ 
Variable dose & 
schedule  
ACC/AHA 
guidelines 
Candidate genes in 
anthracycline 
metabolism and 
NADPH, HFE, 
ABCC2 
 No 
24 
 
pharmacodynamics 
Lubienie
cka et al.9 
91 Retrospective 
adult cohort  
Daunorubicin / 
Variable dose  & 
schedule   
Acute 
cardiotoxicity,  
60 Candidate genes 
in anthracycline 
metabolism and 
efflux 
POR No 
Sachidan 
andam et 
al.10 
2 Two adult sisters 
with CHF  
Doxorubicin/ 
Variable dose & 
schedule 
Sister 1 - cardiac 
transplant. 
Sister 2 - LVEF 
dropped to 22% 
Candidate gene 
ABCC1, NADPH, 
CBR1, CBR3, 
HMNT and ABCB4 
HNMT No 
Wang et 
al.11 
287 COG-
ALTE03N1 
Any anthracycline / 
Variable dose & 
schedule 
AHA guidelines 2100 Candidate 
genes on 
ITMAT/Broad 
CARe 
cardiovascular SNP 
array 
HAS3 Yes 
 
Visscher 
et al.12 
344 Retrospective 
pediatric cohort  
Doxorubicin & 
Daunorubicin/  
variable dose & 
schedule  
CTCAE v3 Candidate 4578 
SNPs in drug 
pharmacokinetic 
and toxicity genes 
SLC22A7, 
SLC22A17 
Yes 
 
Aminken
g et al.13 
280 Retrospective 
pediatric cohort  
Doxorubicin & 
Daunorubicin/  
Variable dose & 
schedule 
CTCAE v3 GWAS RARG Yes –Two 
cohorts 
Schneide
r et al. 
(current 
study) 
102 ECOG-5103 Doxorubicin/ 
Uniform dose & 
schedule  
cardiologist 
adjudicated 
GWAS rs28714259 in 
intergenic 
region of chr 15 
Yes-Two 
cohorts  
 
ACC = American College of Cardiology; AHA =American Heart Association ; ALL= acute lymphoblastic leukemia; AML = Acute myeloid leukemia; CHF = 
Congestive Heart Failure; COG = Children's Oncology Group; CTCAE = Common Terminology Criteria for Adverse Events; DSHNHL = German High-Grade 
Non-Hodgkin's Lymphoma Study Group; ECG = Electrocardiogram; ECHO = Echocardiogram; ECOG = Eastern Cooperative Oncology Group; HCT = 
Hematopoietic cell transplantation; LVES = Left Ventricular Ejection Fraction; LVFS = Left Ventricular Fractional Shortening; WHO = World Health 
Organization 
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FIGURE LEGENDS 
 
FIGURE 1. Consort Diagram. A) E5103-(the genome wide discovery cohort); B) E1199-(first 
candidate SNP validation cohort); C) BEATRICE-(second candidate SNP validation cohort). 
 
FIGURE 2. Flow diagram for candidate SNP selection. 
 
FIGURE 3.  CHF GWAS in EA cohort in E5103. A) Manhattan plot for centrally reviewed, 
cardiologist-adjudicated congestive heart failure from EA. X-axis indicates the chromosomal 
position of each SNP analyzed; Y-axis denotes magnitude of the evidence for association, shown 
as –log10(p-value). SNPs genotyped in the two independent samples are circled; B) p-values 
(−log10) of SNPs near rs28714259 from SNP association analysis with CHF. SNPs are colored to 
reflect their LD with rs28714259.  
 
 
Figure 1. A
602 samples removed due to 
low DNA concentration
142 samples removed due to 
unacceptable genotyping call
83 samples removed due to 
duplicate genotyping data or 
DNA from male patients.
3101 patients without an event
794 EA 
patients
987 patients defined as 
controls
2114 patients removed due to 
incomplete treatment or dose 
modifications impacting 
cumulative anthracycline dose
93 AA 
patients
100 patients 
of other race
4 patients of 
other race 
with CHF
51 EA 
patients 
with CHF
13 AA 
patients 
with CHF
37 samples removed due to 
unavailable clinical data
68 patients with CHF
3169 samples for analysis
4033 samples available
3252 samples successfully genotyped
3394 samples  with  clinical available data 
3431 samples genotyped
2906 samples genotyped
47 patients with 
CHF
2415 samples successfully genotyped
491 samples removed due to 
unacceptable genotyping call
2368 patients without 
an event
1485 samples removed 
due to dose modifications 
impacting cumulative 
anthracycline dose 883 patients 
defined as controls
737 
Caucasia
n controls
38 
Caucasian 
patients 
with CHF
7 African 
American 
patients 
with CHF
66 controls 
of other race
2 patients 
of other 
race with 
CHF
80 African 
American 
controls
Figure 1. B
832 samples available
4 duplicate samples removed 
828 samples with available clinical data
804 patients without an event
298 patients 
defined as controls
506 patients removed due 
to incomplete treatment or 
dosage adjustment 
impacting intended 
anthracycline dose
24 patients with LVEF ≤ 45%
2 patients of 
other race 
with event
21 
Caucasian 
patients with 
event
1 African 
American 
patients 
with event
24 controls 
of other 
race
266 
Caucasian 
controls
8 African 
American  
controls
Figure 1. C


Supplement Material 
Due to the availability of germline DNA, genotyping was performed at two independent time 
points in non-overlapping study subsets. DNA from an initial 2209 patients was genotyped by 
Illumina Genotyping Services using the HumanOmni1-Quad (>1 million SNPs) array. An 
additional 1222 patients were also genotyped by Illumina Genotyping Services using the Human 
OmniExpress (730,525 SNPs) array. Both sample sets used the Illumina BeadChip microarray 
platform for genotyping and the Illumina GenomeStudio software for initial genotyping calls. Of 
note, SNPs on the OmniExpress were a subset of those on the HumanOmni1-Quad. Those SNPs 
not on the HumanOmni1-Quad were imputed in the second sample. Briefly, the 1000 Genomes 
Phase I integrated variant set served as reference using the IMPUTE2 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html#references) software. All SNPs were 
mapped to the human genome version GRCh37.3. Prior to imputation, SNPs with missing rate 
greater than 5%, Hardy Weinberg Equilibrium (HWE) p-values less than 0.0001, or minor allele 
frequency (MAF) less than 3% were excluded. A principal component analysis was performed 
using Eigenstrat20,21 and reference data from 11 HapMap phase III populations to identify 
clusters using the first two eigenvectors computed using all SNPs (see figure below).Samples 
clustering with the European American (EA) reference set were retained for further analysis.  
 
Genotypes from both sets were imputed to the level of the 1000 Genome Project. Imputation was 
performed with the 1000 Genomes Phase I integrated variant set as reference haplotypes, using 
the IMPUTE2 software, and all SNPs were mapped to the human genome version GRCh37.3. 
SNPs having  low imputation quality (information score <0.30) were removed from further 
analysis.810,907 SNPs were used in EA samples.  
Ch RSID BP Effect (minor) Allele Alternative (major) Allele MAF OR Pvalue
14 rs2184559 56192541 G A 0.10 2.71 2.76E-06
2 rs12614202 77688109 T C 0.40 0.37 3.87E-06
20 rs12480103 52338770 A G 0.30 2.47 4.94E-06
13 rs9557321 100521101 C T 0.06 2.62 6.77E-06
2 rs7596623 12890650 C T 0.10 2.37 6.78E-06
5 rs6883259 7440084 G A 0.21 2.13 8.59E-06
5 rs766643 7446889 G A 0.21 2.11 8.92E-06
8 rs12545665 70373263 T C 0.04 2.37 9.23E-06
15 rs28714259 23708527 A G 0.09 2.10 9.25E-06
15 rs28684656 23708446 C T 0.09 2.10 9.37E-06
18 rs4058287 55995721 G A 0.48 0.41 9.68E-06
5 rs7710510 7427289 T C 0.21 2.13 1.01E-05
15 rs1875910 23708851 T C 0.09 2.08 1.03E-05
11 rs7111513 124733377 C T 0.25 2.02 1.10E-05
8 rs11203734 15795898 G A 0.05 3.08 1.17E-05
22 kgp8105491 46644177 A G 0.06 2.71 1.19E-05
8 rs2410329 15818278 T C 0.07 3.14 1.25E-05
3 rs9879227 193174782 C T 0.07 2.51 1.32E-05
1 rs7522389 19973358 T G 0.21 2.66 1.42E-05
20 rs76464104 22210602 T C 0.04 1.38 1.59E-05
1 rs10857972 109384436 T C 0.25 0.32 1.85E-05
1 rs6704266 109386174 G A 0.25 0.32 1.85E-05
11 rs5017048 124734471 T G 0.25 2.02 1.93E-05
13 rs1745836 47337846 C T 0.23 2.39 1.96E-05
2 rs6752623 176950926 A G 0.18 2.54 1.97E-05
4 rs13125385 32469424 A C 0.08 2.05 1.98E-05
18 rs12051934 56004003 G A 0.48 0.41 2.12E-05
12 rs7399293 19363948 T C 0.08 2.38 2.18E-05
8 rs16908579 82007370 C A 0.05 2.60 2.35E-05
8 rs1503366 68435226 C T 0.37 1.65 2.38E-05
6 rs1204328 72427371 C A 0.03 3.04 2.52E-05
22 rs4253763 46622600 C T 0.06 2.90 2.61E-05
22 rs16983347 18900868 A G 0.04 3.64 2.71E-05
7 rs7777356 134519965 A G 0.08 2.64 2.85E-05
8 rs11781908 68347055 A G 0.17 1.72 2.87E-05
10 rs7094302 77971599 C T 0.18 1.95 2.90E-05
9 rs7869360 19712170 A G 0.05 2.13 2.92E-05
8 rs12548222 19977258 G A 0.11 2.05 3.14E-05
8 rs7016422 15813380 A G 0.07 2.94 3.19E-05
2 rs13397389 12907238 T C 0.11 2.13 3.33E-05
6 rs115541994 32381939 C T 0.33 2.09 3.36E-05
5 rs6871111 102273022 G A 0.05 2.21 3.38E-05
22 rs7291763 46646162 A C 0.05 2.84 3.49E-05
4 rs6449090 9884536 C T 0.31 2.53 3.61E-05
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4 rs10012367 40746613 G A 0.41 2.15 3.66E-05
1 rs7523079 19962874 C T 0.21 2.50 3.69E-05
3 rs11710776 106971327 C T 0.12 2.51 3.76E-05
4 rs4697900 9859976 G A 0.40 2.39 3.87E-05
5 rs32680 102191715 T C 0.24 2.14 3.89E-05
11 rs10894749 133682252 A G 0.43 0.44 4.02E-05
8 rs11779485 68390435 A C 0.36 1.66 4.04E-05
11 rs1365120 36438075 C T 0.10 2.23 4.05E-05
2 rs13413220 12907151 C T 0.11 2.00 4.07E-05
10 rs7068881 16838866 G A 0.24 2.52 4.27E-05
14 rs1354 55406992 A G 0.03 2.54 4.40E-05
4 kgp8283262 10272013 T C 0.07 3.05 4.54E-05
6 rs2489944 161292913 T C 0.17 2.38 4.69E-05
13 rs7994896 65528335 C T 0.04 2.74 4.72E-05
13 rs925558 65524120 T C 0.04 2.74 4.73E-05
3 rs13087409 118077682 C A 0.09 2.66 4.74E-05
13 rs1513001 65526287 T C 0.04 2.74 4.74E-05
9 rs7855757 19712378 C T 0.05 2.00 4.88E-05
3 rs10510504 20797722 C T 0.13 0.12 4.96E-05
8 rs4737838 68420477 C A 0.36 1.64 5.01E-05
5 rs6860588 102280302 T C 0.30 2.02 5.02E-05
8 rs7827961 68408438 T C 0.35 1.66 5.05E-05
1 rs10753081 173443531 T C 0.30 1.89 5.10E-05
13 rs12863645 101395935 G T 0.14 1.71 5.21E-05
4 rs11727143 40739635 T C 0.41 2.16 5.23E-05
22 rs11090819 46626506 A G 0.06 2.53 5.32E-05
12 rs2238161 120804508 G C 0.05 3.03 5.45E-05
2 rs17014128 77689016 C T 0.17 0.19 5.48E-05
17 rs10514983 49555822 A G 0.05 3.67 5.50E-05
1 rs10798282 173437024 C T 0.30 1.87 5.54E-05
16 rs1468171 13466323 C T 0.19 2.42 5.62E-05
8 rs13273765 1146100 G A 0.47 1.96 5.63E-05
3 rs779206 118023515 G A 0.26 0.43 5.67E-05
2 rs11123997 105187436 A G 0.14 1.98 5.67E-05
2 rs6746423 41267941 A G 0.05 2.58 5.82E-05
7 rs10248605 26173027 G A 0.11 2.78 5.89E-05
12 rs16950058 120750517 G A 0.05 3.03 6.02E-05
12 rs5634 120762837 G A 0.05 3.03 6.02E-05
8 rs7820882 68389059 T C 0.35 1.64 6.10E-05
3 rs11715178 20764798 A G 0.14 0.12 6.19E-05
18 rs1458866 30037985 C T 0.15 2.36 6.22E-05
1 rs4916358 173423799 G A 0.30 1.86 6.76E-05
4 kgp5440207 10326390 T C 0.07 2.96 6.85E-05
13 rs342715 92383193 G A 0.24 0.28 6.88E-05
5 rs11952361 102287920 G A 0.31 1.94 7.01E-05
6 rs2465874 161298592 A C 0.19 2.32 7.09E-05
6 rs2233980 31079644 A G 0.08 2.36 7.44E-05
4 rs13148112 138118905 G A 0.26 1.96 7.61E-05
5 rs3776874 102282317 T C 0.31 1.94 7.81E-05
4 rs9684729 9862036 T C 0.34 2.45 7.94E-05
4 rs6553973 177531472 T C 0.22 2.02 8.34E-05
9 rs776777 18657487 A C 0.45 0.45 8.36E-05
6 rs36022097 26995168 A G 0.11 2.45 8.39E-05
13 rs171060 92387945 C T 0.24 0.29 8.82E-05
7 rs17138749 116133098 C A 0.16 2.05 8.86E-05
8 rs428300 142173356 C T 0.37 2.11 8.90E-05
16 rs1018891 13457714 G A 0.17 2.43 8.99E-05
5 rs250594 164065767 C T 0.43 2.09 9.06E-05
15 rs4238475 94135579 A C 0.37 2.39 9.06E-05
2 rs6722342 12888761 T C 0.10 2.12 9.11E-05
8 rs12549742 15815994 T G 0.04 3.52 9.30E-05
11 rs10836550 36427893 G A 0.14 2.21 9.42E-05
10 rs7068265 16838417 G A 0.29 2.18 9.56E-05
7 rs17162825 10298689 G A 0.13 2.49 9.60E-05
16 rs886218 13464491 T C 0.17 2.44 9.65E-05
14 rs7146775 55407757 A G 0.03 2.50 9.70E-05
16 rs2188738 13441954 G A 0.17 2.42 9.72E-05
4 kgp11734686 9912993 C T 0.26 2.16 9.78E-05
